ACP: ASCVD Risk Estimation for Primary Prevention with Donald Lloyd-Jones, MD, ScM
"Risk estimators do not prescribe a drug," says Dr Lloyd-Jones. They are tools to help make the decision to prescribe the drug. He explains how to use them in primary care.
“Risk estimators do NOT prescribe a drug,” said Donald Lloyd-Jones, MD, ScM, underscoring the role of cardiovascular risk assessment in primary prevention. The risk estimator is a tool to help guide decision making about whether drug therapy—and what level of intensity—is appropriate in a given patient to prevent atherosclerotic cardiovascular disease (ASCVD).
It is a starting point in a process, he points out, that involves both the science and the art of medicine plus a large dose of shared decision making between physician and patient to arrive at an individualized approach to treatment.
Lloyd-Jones made his comments during his presentation, “Preventive cardiology: cardiovascular screening and imaging for risk stratification,” at the American College of Physicians Internal Medicine Meeting 2021: Virtual Experience on Friday, April 30, 2021.
The slide show that follows is based on Dr Lloyd-Jones' presentation and includes links to all of the primary studies that he discusses.
Donald Lloyd-Jones, MD, ScM is the Eileen M. Foell Professor of Heart Research; Professor of Preventive Medicine, Medicine, and Pediatrics; Chair, Department of Preventive Medicine, at the Northwestern University Feinberg School of Medicine, Chicago, IL, and President-Elect of the American Heart Association.
FDA Proposed Rule Would Limit Nicotine Content in Cigarettes, Cigars, Other Combusted Products
January 16th 2025The agency estimates that limiting nicotine levels could lead to 1.8 million fewer tobacco-related deaths by 2060 and health care savings of $1.1 trillion a year over the next 40 years.
